Subscribe to RSS
DOI: 10.1055/a-2447-8463
Iterative Development of a Clinical Decision Support Tool to Enhance Naloxone Coprescribing
Funding None.
Abstract
Background Opioid overdoses have contributed significantly to mortality in the United States. Despite long-standing recommendations from the Centers for Disease Control and Prevention to coprescribe naloxone for patients receiving opioids who are at high risk of overdose, compliance with these guidelines has remained low.
Objectives The objective of this study was to develop and evaluate a hospital-wide electronic health record (EHR)-based clinical decision support (CDS) tool designed to promote naloxone coprescription for high-risk opioids.
Methods We employed an iterative approach to develop a point-of-order, interruptive EHR alert as the primary intervention and assessed naloxone prescription rates, EHR efficiency metrics, and barriers to adoption. Data were obtained from our EHR's clinical data warehouse and analyzed using statistical process control with odds ratios calculated to quantify statistically significant differences in prescribing rates during the intervention periods.
Results The initial implementation phase of the intervention, spanning from April 2019 to May 2022, yielded a nearly 3-fold increase in the proportion of high-risk patients receiving naloxone, rising from 13.4% (95% confidence interval [CI], 12.9–13.8%) to 36.4% (95% CI, 35.2–37.5%; p = 10−38). Enhancements to the CDS design and logic during the subsequent iteration's study period, June 2022 and December 2023, reduced the number of CDS triggers by more than 30-fold while simultaneously driving an additional increase in naloxone receipt to 42.7% (95% CI, 40.6–44.8%; p = 2 × 10−5). The efficiency of the CDS demonstrated marked improvement, with prescribers accepting the naloxone coprescription recommendation provided by the CDS in 41.1% of the encounters in version 2, compared with 6.2% in version 1 (p = 6 × 10−9).
Conclusion This study offers a sustainable and scalable model to address low rates of naloxone coprescription and may also be used to target other opportunities for improving guideline-concordant prescribing practices.
Protection of Human and Animal Subjects
Human and animal subjects were not utilized in this study. This study was determined to be quality improvement and was exempt from Institutional Review Board review.
Publication History
Received: 21 June 2024
Accepted: 22 October 2024
Accepted Manuscript online:
25 October 2024
Article published online:
05 March 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Opioid Overdose Deaths and Opioid Overdose Deaths as a Percent of All Drug Overdose Deaths [website]. KFF, 2021 . Accessed January 9, 2024 at: https://www.kff.org/other/state-indicator/opioid-overdose-deaths
- 2 Opioid Overdose [website]. Centers for Disease Control and Prevention. 2023 . Accessed January 11, 2024 at: https://www.cdc.gov/drugoverdose/deaths/opioid-overdose.html
- 3 Risk Factors for Opioid Misuse, Addiction, and Overdose [website]. US Department of Labor, 2024 . Accessed September 3, 2024 at: https://www.dol.gov/agencies/owcp/opioids/riskfactors
- 4 Preventing Opioid Overdose [website]. Centers for Disease Control and Prevention. 2024 . Accessed September 3, 2024 at: https://www.cdc.gov/overdose-prevention/prevention/index.html
- 5 Naloxone DrugFacts [website]. National Institute on Drug Abuse, 2022 . Accessed January 11, 2024 at: https://nida.nih.gov/publications/drugfacts/naloxone
- 6 Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 2022; 71 (3, No. RR-3): 1-95
- 7 Guy Jr GP, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018. MMWR Morb Mortal Wkly Rep 2019; 68 (31) 679-686
- 8 Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open 2019; 2 (05) e193209
- 9 Lin LA, Brummett CM, Waljee JF, Englesbe MJ, Gunaseelan V, Bohnert ASB. Association of opioid overdose risk factors and naloxone prescribing in US adults. J Gen Intern Med 2020; 35 (02) 420-427
- 10 Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D program, United States, 2016-2017. JAMA 2019; 322 (05) 462-464
- 11 Drainoni ML, Koppelman EA, Feldman JA. et al. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. BMC Res Notes 2016; 9 (01) 465
- 12 Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: a systematic review. Prev Med 2018; 114: 79-87
- 13 Opioid Risk Tool—OUD (ORT-OUD) [website]. National Institute on Drug Abuse. 2021 . Accessed September 3, 2024 at: https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/opioid-risk-tool-oud-ort-oud
- 14 Funke M, Kaplan MC, Glover H. et al. Increasing naloxone prescribing in the emergency department through education and electronic medical record work-aids. Jt Comm J Qual Patient Saf 2021; 47 (06) 364-375
- 15 Freise JE, McCarthy EE, Guy M, Steiger S, Sheu L. Increasing naloxone co-prescription for patients on chronic opioids: a student-led initiative. J Gen Intern Med 2018; 33 (06) 797-798
- 16 Wilson CG, Rodriguez F, Carrington AC, Fagan EB. Development of a targeted naloxone coprescribing program in a primary care practice. J Am Pharm Assoc (Wash DC) 2017; 57 (2S): S130-S134
- 17 Crusco S, Smith E, Rajupet S. Improving intranasal naloxone prescribing through EMR modification and automation. J Addict Med 2021; 15 (03) 181-186
- 18 Duan L, Lee MS, Adams JL, Sharp AL, Doctor JN. Opioid and naloxone prescribing following insertion of prompts in the electronic health record to encourage compliance with California State Opioid Law. JAMA Netw Open 2022; 5 (05) e229723
- 19 Siff JE, Margolius D, Papp J, Boulanger B, Watts B. A healthcare system-level intervention to increase naloxone availability for patients with opioid prescriptions. Am J Addict 2021; 30 (02) 179-182
- 20 Nelson SD, McCoy AB, Rector H. et al. Assessment of a naloxone coprescribing alert for patients at risk of opioid overdose: a quality improvement project. Anesth Analg 2022; 135 (01) 26-34
- 21 Srikumar JK, Daniel K, Balasanova AA. Implementation of a naloxone Best Practice Advisory into an electronic health record. J Addict Med 2023; 17 (03) 346-348
- 22 Co Z, Classen DC, Cole JM. et al. How safe are outpatient electronic health records? An evaluation of medication-related decision support using the ambulatory electronic health record evaluation tool. Appl Clin Inform 2023; 14 (05) 981-991
- 23 Rabbani N, Ho M, Dash D, Calway T, Morse K, Chadwick W. Pseudorandomized testing of a discharge medication alert to reduce free-text prescribing. Appl Clin Inform 2023; 14 (03) 470-477
- 24 Langley GJ. The improvement guide: a practical approach to enhancing organizational performance. 2nd ed. San Francisco:: Jossey-Bass,; 2009
- 25 Ancker JS, Edwards A, Nosal S, Hauser D, Mauer E, Kaushal R. with the HITEC Investigators. Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Inform Decis Mak 2017; 17 (01) 36
- 26 Bauer J, Busse M, Kopetzky T, Seggewies C, Fromm MF, Dörje F. Interprofessional evaluation of a medication clinical decision support system prior to implementation. Appl Clin Inform 2024; 15 (03) 637-649
- 27 Dolin RH, Shenvi E, Alvarez C. et al. PillHarmonics: an orchestrated pharmacogenetics medication clinical decision support service. Appl Clin Inform 2024; 15 (02) 378-387
- 28 What is clinical decision support? [website]. Centers for Disease Control and Prevention. 2022 . Accessed February 27, 2024 at: https://www.cdc.gov/opioids/healthcareadmins/ehr/clinical-decision-support.html
- 29 Jachimowicz JM, Duncan S, Weber EU, Johnson EJ. When and why defaults influence decisions: a meta-analysis of default effects. Behavioural Public Policy. 2019;3(2):159–186. Massachusetts Naloxone Standing Order of 2020 [website]. Massachusetts Department of Public Health. 2020 . Accessed at: https://www.mass.gov/doc/naloxone-standing-order-1/download
- 30 SAMSHA 2019 new and continuation grant awards by state [website]. SAMSHA. 2019 . Accessed at: https://www.samhsa.gov/sites/default/files/grants/2019-new-continuation-grant-awards-by-state.pdf
- 31 Data brief on overdose education and naloxone distribution programs [website]. Massachusetts Department of Public Health. 2019 . Accessed at: https://www.mass.gov/doc/data-brief-overdose-education-and-naloxone-distribution-programs/download
- 32 Westbrook JI, Woods A, Rob MI, Dunsmuir WTM, Day RO. Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med 2010; 170 (08) 683-690
- 33 EDawson T, Beus J, WOrenstein E, Umontuen U, McNeill D, Kandaswamy S. Reducing therapeutic duplication in inpatient medication orders. Appl Clin Inform 2023; 14 (03) 538-543
- 34 Miller SD, Murphy Z, Gray JH. et al. Human-centered design of a clinical decision support for anemia screening in children with inflammatory bowel disease. Appl Clin Inform 2023; 14 (02) 345-353